Price
No data yet.
Social Signal Score
Analyst Ratings
38 analystsRevenue
$51.43B+136.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gail Koziara Boudreaux
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Employees
- 96,615
- Beta
- 0.71
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.01
Financials
Revenue
$51.43B+136.7%Net Income
$1.36B+270.5%EBITDA
$2.52B+176.7%Free Cash Flow
$1.00B+837.2%EPS (diluted)
$6.27+357.7%Shares Outstanding (diluted)
217.60M-19.0%Operating Expenses
$5.75BCash & Debt
$37.85BReturn of Capital
$703.00MRevenue by Segment (annual)
$197.12BDividend per Share
$1.72Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $199.13B | $5.66B | $25.18 |
| 2024 | $176.81B | $5.98B | $25.81 |
| 2023 | $171.34B | $5.99B | $25.38 |
| 2022 | $156.59B | $5.89B | $24.56 |
| 2021 | $138.64B | $6.10B | $25.25 |
| 2020 | $121.87B | $4.57B | $18.23 |
| 2019 | $104.21B | $4.81B | $18.81 |
| 2018 | $92.11B | $3.75B | $14.53 |
| 2017 | $90.04B | $3.84B | $14.70 |
| 2016 | $84.98B | $2.47B | $9.39 |
| 2015 | $79.24B | $2.56B | $9.73 |
| 2014 | $73.92B | $2.57B | $9.31 |
| 2013 | $71.12B | $2.65B | $8.89 |
| 2012 | $61.53B | $2.66B | $8.26 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ELV's reported EPS growth of 9.0% a year over 13 years.
- EPS in 5 years
- $39.28
- Implied price
- $549.88
- Return from $392.58
- 7.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $273.39 — -30.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -1.0% | -9.2% | -5.8% | -2.8% | -0.2% | 2.2% |
| 4.0% | -4.6% | -1.0% | 2.1% | 4.8% | 7.3% |
| 9.0% | 0.0% | 3.7% | 7.0% | 9.9% | 12.5% |
| 14.0% | 4.6% | 8.5% | 11.9% | 14.9% | 17.6% |
| 19.0% | 9.2% | 13.2% | 16.8% | 19.9% | 22.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (34)
- Newszacks.com·6d ago·Neutral
Can Medicaid Rate Improvements Drive Elevance's 2027 Margin Recovery? ELV eyes a Medicaid margin recovery in 2027 as reimbursement rates improve, but elevated medical costs and uneven state adjustments remain key hurdles.
View source ↗ - Newsmarketbeat.com·9d ago·Neutral
Elevance Health Targets 12% Earnings Growth in 2027 as Insurance Margins Recover Elevance Health NYSE: ELV expects adjusted earnings per share to grow at least 12% in 2027 from its recently increased 2026 baseline of at least $26.75, Chief Financial Officer Mark Kaye said at a UBS conference.
View source ↗ - News (RSS)economictimes·18d ago·Neutral
AI data center stocks dip, renewables surge after Democrat sweep in US midterm elections Data center stocks slid on Wednesday, while clean-energy shares rallied after Democrats seized control of Congress, prompting investors to reposition for tougher scrutiny of the AI boom and a shift in policy priorities.The Democratic sweep, which included victories in traditional Republican strongholds and key data-center hubs Texas and Georgia, will usher in divided government in Washington and raises the p
View source ↗ - Newszacks.com·23d ago·Neutral
Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know Does Elevance Health (ELV) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·27d ago·Neutral
Implied Volatility Surging for Elevance Health Stock Options Investors need to pay close attention to ELV stock based on the movements in the options market lately.
View source ↗ - News (RSS)seekingalpha·31d ago·Negative
Elevance Health: Better Results, But Not Enough To Buy
View source ↗ - News (RSS)fool·31d ago·Positive
Elevance: 3 Key Takeaways for Long-Term Investors Clinical efficiency gains and integrated pharmacy benefits are lengthening the runway for margin expansion beyond 2026.
View source ↗ - Newsseekingalpha.com·31d ago·Neutral
Elevance Health: Better Results, But Not Enough To Buy Elevance Health raised its 2026 adjusted EPS guidance to at least $29, but the sustainability of its earnings recovery remains uncertain. Third-quarter adjusted EPS rose 15.9%, while nine-month operating gain declined 25.7%, highlighting the gap between improving earnings and underlying profitability. Health Benefits margins remain under pressure, particularly in Medicaid, despite improving medical cost trends and stronger quarterly results.
View source ↗ - Newsfool.com·31d ago·Negative
Elevance: 3 Key Takeaways for Long-Term Investors Elevance raised its 2026 earnings baseline to at least $26.75 per share. Carelon's cancer program reduced avoidable inpatient admissions by 15%.
View source ↗ - News (RSS)fool·32d ago·Positive
Elevance (ELV) Q3 2026 Earnings Call Transcript CEO Boudreaux raised full-year guidance on Medicaid improvements and Carelon momentum.
View source ↗ - Newszacks.com·32d ago·Positive
Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run? Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - News (RSS)seekingalpha·32d ago·Positive
Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·32d ago·Positive
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
View source ↗ - Newsmarketbeat.com·32d ago·Neutral
What Elevance Health (ELV) Said on Its Q3 Earnings Call Elevance Health NYSE: ELV raised its 2026 earnings outlook after reporting third-quarter adjusted diluted earnings per share of $6.99, exceeding the company's expectations as Medicaid, Medicare Advantage and Individual ACA businesses all performed better than anticipated.
View source ↗ - Newszacks.com·32d ago·Negative
Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newswsj.com·32d ago·Negative
Elevance Health Raises Yearly Outlook as Profit, Revenue Rise For the third quarter, the health-insurance company reported a rise in net income to $1.34 billion, or $6.27 a share, compared with $1.19 billion, or $5.32 a share, a year earlier.
View source ↗ - Newsreuters.com·32d ago·Neutral
Elevance lifts 2026 profit forecast on better medical cost management Elevance lifts 2026 profit forecast on better medical cost management
View source ↗ - Newsbusinesswire.com·32d ago·Positive
Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported third quarter 2026 results ahead of expectations. "Elevance Health's third quarter results reflect stronger execution across our diversified portfolio and underscore the earnings power of the business. We are raising our 2026 earnings outlook and remain confident in delivering at least 12% growth in adjusted diluted earnings per share in 2027 fro…
View source ↗ - News (RSS)financialpost·33d ago·Neutral
Elevra Lithium September 2026 Quarterly Report Advisory BRISBANE, Australia, Oct. 20, 2026 (GLOBE NEWSWIRE) — North American lithium producer Elevra Lithium Limited (ASX:ELV; NASDAQ:ELVR) (“Elevra” or “Company”) advises that the Company’s September 2026 Quarterly Activities Report is scheduled for release on Tuesday, 27 October 2026. The Company will host an investor webcast covering the September 2026 Quarterly results commencing at 9:30am AEDT […]
View source ↗ - News (RSS)seekingalpha·33d ago·Neutral
Elevance Health Q3 2026 Earnings Preview
View source ↗ - News (RSS)seekingalpha·34d ago·Neutral
Elevance Health: Why I Don't Believe In The Stock At This Price
View source ↗ - Newszacks.com·37d ago·Negative
Unveiling Elevance Health (ELV) Q3 Outlook: Wall Street Estimates for Key Metrics Besides Wall Street's top-and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
View source ↗ - Newszacks.com·38d ago·Negative
Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? Can ELV overcome a 4.9% premium decline and weaker Health Benefits income? Membership losses add pressure, though higher product revenues may offer some relief.
View source ↗ - News (RSS)zerohedge·60d ago·Negative
White House Cancels Coverage For 750,000 ACA Enrollees, Citing Fraud White House Cancels Coverage For 750,000 ACA Enrollees, Citing Fraud Vice President JD Vance said Tuesday that about 750,000 people on Affordable Care Act plans were never entitled to the coverage, and that pulling their subsidies will save taxpayers $2.2 billion. Mehmet Oz, who runs the Centers for Medicare and Medicaid Services, stood with him. The savings number is an administration estimate. The Congressional Budget Office
View source ↗ - News (RSS)seekingalpha·70d ago·Neutral
Elevance leads UBS health benefits survey as employers brace for higher costs
View source ↗ - News (RSS)forbes·70d ago·Neutral
Is The Health Insurer Rebound Complete? Some Seem To Think So An increasing number of industry analysts say costs are under control for the likes of CVS Health, Centene, Cigna, Elevance Health, Humana, UnitedHealth Group and others.
View source ↗ - Newsbenzinga.com·73d ago·Neutral
Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation Elevance Health Inc. (NYSE:ELV) shares are jumping Thursday after the company reaffirmed its full-year 2026 earnings guidance ahead of a series of investor meetings. Here's what you should know.
View source ↗ - News (RSS)financialpost·75d ago·Neutral
Elevra Lithium Announces NAL Expansion Pre-Feasibility Study BRISBANE, Australia, Sept. 08, 2026 (GLOBE NEWSWIRE) — North American lithium producer Elevra Lithium Limited (“Elevra” or “Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce the results of a Pre-Feasibility Study (“PFS”) for the staged North American Lithium (“NAL”) Brownfield Expansion in Québec. The PFS confirms the NAL Expansion as a high-value growth project that is […]
View source ↗ - News (RSS)businessinsider·75d ago·Neutral
Elevra Lithium Announces NAL Expansion Pre-Feasibility Study <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify">BRISBANE, Australia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra" or "Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce the results of a Pre-Feasibility Study ("PFS")...
View source ↗ - News (RSS)yahoo·82d ago·Neutral
Elevance Health (ELV) Soars as Investors Gain Confidence in Profitability
View source ↗ - News (RSS)yahoo·82d ago·Neutral
Elevance Health (ELV): Bridging the Gap between Care and Coverage
View source ↗ - News (RSS)yahoo·89d ago·Neutral
Is Elevance Health (ELV) a Mispriced Opportunity?
View source ↗ - Newszacks.com·100d ago·Neutral
Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue? Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Wed, Jan 27(in 2 months)
Consensus estimate $2.08 per share
Typical surprise +16.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 21$6.99 vs $4.71beat
- Wed, Jul 15$7.45 vs $6.21beat
- Wed, Apr 22$12.58 vs $10.82beat
- Wed, Jan 28$3.33 vs $3.10beat
- Tue, Oct 21$6.03 vs $4.93beat
- Thu, Jul 17$8.84 vs $8.91miss
Estimates and results for ELV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELV officers and directors.
- Bought
- $2.6m
- Sold
- $7.0m
5 trades
19 trades
- Lavu Ratnakarsold
- Kaye Marksold
- Kaye Marksold
- Kaye Marksold
- Kaye Marksold
- Kaye Marksold
- Kaye Marksold
- Kaye Marksold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Jan 16, 2026 (18d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 26, 2025 (550d later)Sell$100,001 - $250,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 12, 2025 (38d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (242d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2025 (10d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$15,001 - $50,000
- Daniel Milton Newhousehouse · WA04 · disclosed May 16, 2025 (35d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 7, 2025 (8d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Apr 9, 2025 (30d later)Sell$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Apr 9, 2025 (30d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
